Vistagen CEO to Present at TD Cowen Healthcare Conference
Event summary
- Vistagen CEO Shawn Singh to present at the 46th Annual TD Cowen Healthcare Conference on March 2, 2026.
- Presentation scheduled for 3:50 p.m. Eastern Time.
- Vistagen focuses on intranasal pherines for neuroscience indications.
- Company's pipeline includes candidates for social anxiety, depression, and menopause symptoms.
The big picture
Vistagen's participation in the TD Cowen Healthcare Conference underscores its push to gain investor attention amid a crowded biopharmaceutical landscape. The company's focus on nose-to-brain neurocircuitry represents a novel approach to treating mental health and menopause symptoms, potentially offering safer alternatives to existing treatments. Success will depend on clinical trial outcomes and regulatory approvals.
What we're watching
- Pipeline Progress
- How Vistagen's intranasal pherines advance through clinical stages.
- Market Positioning
- Whether Vistagen can differentiate itself in the competitive neuroscience space.
- Investor Sentiment
- The impact of conference presentation on Vistagen's stock performance.